Latest US Analyst Ratings: March 12th, 2026

Analyst Ratings (USA)

Today’s 408 U.S. analyst ratings show a mix of cautious optimism and selective buying opportunities across sectors. Major tech and energy names like Apple, NVIDIA, Chevron, and ConocoPhillips continue to see strong buy or overweight endorsements with raised price targets, reflecting confidence in growth and energy demand. Financials and airlines have mixed views, with several Hold or Neutral ratings amid economic uncertainty and margin pressures. Healthcare and biotech updates are active, with new coverage initiations and price target adjustments signaling both high potential and volatility. Overall, analysts are balancing growth prospects with caution, favoring established leaders while trimming targets on more cyclical or overextended names.

Alcoa – AA: UBS Group raised the price target to $70 from $48 with a Neutral rating; Wells Fargo & Company set a $68 target.

American Airlines Group – AAL: Jefferies Financial Group lowered the target to $12 from $15 and maintained a Hold rating.

Ascentage Pharma Group International – AAPG: BTIG Research initiated coverage with a Buy rating and $48 price target.

Apple – AAPL: KeyCorp reiterated a Sector Weight rating.

AbbVie – ABBV: Guggenheim reiterated a Buy rating.

Acco Brands – ACCO: Barrington Research cut the price target to $5 from $6 with an Outperform rating.

ProFrac – ACDC: UBS Group reiterated a Positive rating.

Acacia Research – ACTG: Craig Hallum raised the price target to $6 from $5 and maintained a Buy rating.

American Electric Power – AEP: JPMorgan Chase & Co. raised the target to $139 from $125 with a Neutral rating.

Grupo Aeromexico – AERO: JPMorgan Chase & Co. lowered the price target to $28 from $28.50 while maintaining an Overweight rating.

Atlas Energy Solutions – AESI: Barclays raised the price target to $11 from $8 with an Underweight rating.

American Healthcare REIT – AHR: Truist Financial set a $57 price target.

Akamai Technologies – AKAM: Raymond James Financial set a $120 price target.

AMETEK – AME: Morgan Stanley raised the target to $235 from $215 with an Equal Weight rating.

Aemetis – AMTX: Loop Capital set a $1.75 price target.

AnaptysBio – ANAB: Wedbush raised the price target to $75 from $60 with an Outperform rating.

Arista Networks – ANET: TD Cowen initiated coverage with a Buy rating and $170 target.

APA Corp – APA: Piper Sandler raised the price target to $37 from $30 with a Neutral rating.

Aptiv – APTV: UBS Group upgraded the stock to Buy from Neutral and raised the target to $97 from $89.

Ardelyx – ARDX: Leerink Partners reiterated an Outperform rating; Williams Trading set a $17 price target.

AdvanSix – ASIX: Loop Capital set a $25 price target.

Aveanna Healthcare – AVAH: Truist Financial set a $10 price target.

AeroVironment – AVAV: Canaccord Genuity Group cut target to $300 from $330; Jefferies Financial Group lowered target to $305 from $390; BTIG Research lowered target to $330 from $415, all maintaining Buy ratings.

ArriVent BioPharma – AVBP: BTIG Research initiated coverage with a Buy rating and $42 target.

Anteris Technologies Global – AVR: Cantor Fitzgerald initiated coverage with an Overweight rating and $15 target.

BridgeBio Pharma – BBIO: Leerink Partners reiterated an Outperform rating with a $98 price target.

Black Hills – BKH: Siebert Williams Shank upgraded the stock to Buy from Hold and raised the target to $82 from $79.

Bumble – BMBL: JPMorgan upgraded to Neutral; Citigroup raised target to $3.90; multiple brokers adjusted targets amid mixed outlooks.

BioMarin Pharmaceutical – BMRN: Jefferies Financial Group reiterated a Buy rating with a $103 target.

Box – BOX: Morgan Stanley lowered the price target to $33 from $38 with an Equal Weight rating.

BP – BP: Piper Sandler raised the price target to $47 from $44 with a Neutral rating.

Braze – BRZE: JPMorgan Chase & Co. lowered the price target to $32 from $45 with an Overweight rating.

biote – BTMD: B. Riley lowered target to $2; TD Cowen to $2.50; National Bank Financial set a $2.50 target.

Peabody Energy – BTU: UBS Group raised the price target to $34.50 from $34 with a Neutral rating.

BrainsWay – BWAY: HC Wainwright cut the price target to $15 from $30 with a Buy rating.

BWX Technologies – BWXT: TD Cowen and TD Securities initiated coverage with Buy ratings and $230 price targets.

Conagra Brands – CAG: Wells Fargo & Company downgraded rating to Underweight from Equal Weight and lowered target to $15 from $20.

Pathward Financial – CASH: Piper Sandler initiated coverage with an Overweight rating and $107 target.

Celanese – CE: Citigroup raised the price target to $81 from $75 and maintained a Buy rating.

Century Aluminum – CENX: Wells Fargo & Company raised the price target to $69 from $61 with an Overweight rating.

Cigna Group – CI: Sanford C. Bernstein upgraded to Outperform from Market Perform and raised target to $358 from $307.

Canadian Natural Resources – CNQ: The Goldman Sachs Group raised price target to $49 from $37 with a Buy rating.

ConocoPhillips – COP: Piper Sandler raised the price target to $154 from $111 with an Overweight rating.

Campbell’s – CPB: Multiple brokers cut targets; several downgraded stock amid weaker outlooks.

Crocs – CROX: Williams Trading upgraded the stock to Hold from Sell with an $84 target.

CSX – CSX: Bank of America lowered the price target to $46 from $48 while maintaining a Buy rating.

Coterra Energy – CTRA: Piper Sandler raised the price target to $47 from $41 with an Overweight rating.

CVS Health – CVS: Sanford C. Bernstein upgraded to Outperform from Market Perform and raised target to $94 from $91.

Chevron – CVX: Piper Sandler raised the price target to $242 from $179 with an Overweight rating.

Delta Air Lines – DAL: Jefferies Financial Group lowered target to $72 from $84 while maintaining a Buy rating.

Dollar General – DG: Multiple brokerages reiterated ratings from Neutral to Buy, with new targets around $139.

Ginkgo Bioworks – DNA: BTIG Research cut the price target to $5 from $9 with a Sell rating.

Devon Energy – DVN: Piper Sandler raised the price target to $67 from $59 with an Overweight rating.

Diamondback Energy – FANG: Piper Sandler raised the price target to $248 from $215 with an Overweight rating.

Franco-Nevada – FNV: HC Wainwright raised the price target to $305 from $285 with a Buy rating.

Corning – GLW: Bank of America raised the price target to $144 from $120 with a Buy rating.

General Mills – GIS: Wells Fargo & Company downgraded the stock to Underweight from Equal Weight and cut target to $35 from $45.

Honeywell – HON: Morgan Stanley raised the price target to $245 from $235 with an Equal Weight rating.

Jabil – JBL: JPMorgan Chase & Co. raised the price target to $300 from $270 with an Overweight rating; Robert W. Baird initiated coverage with an Outperform rating and $275 target.

Jefferies Financial Group – JEF: UBS Group lowered target to $59 from $76 with a Buy rating; Goldman Sachs Group cut target to $54 from $61 and maintained Buy rating.

Joby Aviation – JOBY: HC Wainwright reiterated a Buy rating with an $18 target.

Kodiak AI – KDK: TD Cowen lowered the price target to $13 from $14 with a Buy rating.

Kinross Gold – KGC: Royal Bank of Canada upgraded to Outperform from Sector Perform and raised target to $45 from $36.

Kraft Heinz – KHC: Wells Fargo & Company lowered the target to $23 from $25 and maintained an Equal Weight rating.

Kamada – KMDA: Benchmark reiterated a Buy rating.

Kohl’s – KSS: Bank of America cut the target to $15 from $18 with an Underperform rating.

Lazard – LAZ: UBS Group lowered the price target to $48 from $59 with a Neutral rating; Goldman Sachs Group reduced target to $46 from $53 and maintained a Sell rating.

Lear – LEA: Royal Bank of Canada initiated coverage with a Sector Perform rating and $135 target.

Levi Strauss & Co. – LEVI: UBS Group reiterated a Buy rating.

LifeMD – LFMD: Loop Capital set a $10 price target.

Lumentum – LITE: TD Cowen initiated coverage with a Hold rating and $675 target.

Liquidia – LQDA: Oppenheimer raised target to $19 from $16 with an Underperform rating.

Life Time Group – LTH: KeyCorp initiated coverage with an Overweight rating and $40 target; UBS Group reiterated a Buy rating with a $43 price target.

Lululemon Athletica – LULU: BTIG Research lowered target to $250 from $303 while maintaining a Buy rating.

Southwest Airlines – LUV: Jefferies Financial Group reduced target to $41 from $48 with a Hold rating.

Lexicon Pharmaceuticals – LXRX: HC Wainwright set a $6 price target.

LSB Industries – LXU: Jefferies Financial Group raised target to $15 from $11 with a Hold rating.

LyondellBasell Industries – LYB: Citigroup upgraded to Buy from Neutral and raised target to $76 from $49; Wells Fargo & Company set a $76 price target.

Live Nation Entertainment – LYV: Goldman Sachs Group raised target to $190 from $175 with a Buy rating.

MBX Biosciences – MBX: TD Cowen reiterated a Buy rating.

Moelis & Company – MC: UBS Group lowered target to $59 from $74 with a Neutral rating; Goldman Sachs Group reduced target to $70 from $80 with a Neutral rating.

MercadoLibre – MELI: JPMorgan Chase & Co. downgraded stock to Neutral from Overweight and cut target to $2,100 from $2,650.

Magnolia Oil & Gas – MGY: Piper Sandler raised target to $31 from $28 with a Neutral rating.

Martin Midstream Partners – MMLP: Stifel Nicolaus lowered target to $3 from $4 with a Hold rating.

Molina Healthcare – MOH: Mizuho cut target to $180 from $220 with an Outperform rating; UBS Group raised target to $151 from $145 with a Neutral rating.

Marathon Petroleum – MPC: Goldman Sachs Group raised target to $239 from $211 with a Buy rating.

Merck & Co. – MRK: Wells Fargo & Company raised price target to $150 from $135 with an Overweight rating.

MGIC Investment – MTG: UBS Group lowered target to $28 from $29.50 with a Neutral rating.

Vail Resorts – MTN: Morgan Stanley reduced target to $147 from $151 with an Equal Weight rating.

Micron Technology – MU: Wells Fargo & Company raised price target to $470 from $410 with an Overweight rating.

Murphy Oil – MUR: Piper Sandler upgraded stock to Overweight from Neutral and raised target to $41 from $33.

Nature’s Sunshine Products – NATR: DA Davidson raised target to $33 from $23 with a Buy rating.

Neurocrine Biosciences – NBIX: JPMorgan Chase & Co. raised target slightly to $177 from $176 with an Overweight rating.

Nanobiotix – NBTX: TD Cowen reiterated a Buy rating.

Minerva Neurosciences – NERV: HC Wainwright reiterated a Neutral rating and raised target to $7 from $4.

National Health Investors – NHI: Truist Financial raised target to $92 from $85 with a Buy rating.

Nike – NKE: Jefferies Financial Group reiterated a Buy rating.

North American Construction Group – NOA: BMO Capital Markets downgraded the stock to Market Perform from Outperform.

Northern Oil and Gas – NOG: Piper Sandler raised target to $32 from $27 with a Neutral rating.

Nutrien – NTR: Jefferies Financial Group upgraded stock to Buy from Hold and raised target to $96 from $74.

Netskope – NTSK: Morgan Stanley, BMO Capital Markets, Royal Bank of Canada, and JPMorgan Chase & Co. lowered targets while maintaining Buy/Outperform ratings.

Novavax – NVAX: Jefferies Financial Group reiterated a Buy rating.

NVIDIA – NVDA: William Blair set target at $300; Cantor Fitzgerald reiterated Overweight rating with $300 target

Navitas Semiconductor – NVTS: Rosenblatt Securities reiterated a Neutral rating with a $7 target.

Orchestra BioMed – OBIO: Chardan Capital reiterated a Buy rating with a $20 target.

Olin – OLN: Citigroup raised target to $26 from $21 with a Neutral rating.

Omada Health – OMDA: JPMorgan Chase & Co. lowered target to $26 from $32 with an Overweight rating.

Oracle – ORCL: Citigroup raised target to $320 from $310 with a Buy rating.

Occidental Petroleum – OXY: Wells Fargo & Company upgraded from Underweight to Overweight, target $69 from $47; Piper Sandler upgraded from Neutral to Overweight, target $66 from $54.

Par Pacific – PARR: Goldman Sachs Group raised target to $53 from $44 with a Neutral rating.

UiPath – PATH: Morgan Stanley lowered target to $17 from $19 with Equal Weight rating.

UiPath – PATH: Mizuho lowered target to $12 from $15 with Neutral rating.

UiPath – PATH: Wells Fargo & Company lowered target to $13 from $14 with Equal Weight rating.

UiPath – PATH: Canaccord Genuity Group lowered target to $15 from $19 with Buy rating.

UiPath – PATH: Truist Financial lowered target to $12 from $17 with Hold rating.

UiPath – PATH: TD Cowen lowered target to $13 from $16 with Hold rating.

UiPath – PATH: DA Davidson lowered target to $13 from $15 with Neutral rating.

UiPath – PATH: UBS Group lowered target to $13 from $17 with Neutral rating.

UiPath – PATH: Needham & Company LLC upgraded rating from Hold to Buy with $15 target.

UiPath – PATH: Bank of America lowered target to $12 from $14 with Underperform rating.

UiPath – PATH: William Blair reiterated Market Perform rating.

PBF Energy – PBF: Goldman Sachs Group raised target to $41 from $33 with a Neutral rating.

Public Service Enterprise Group – PEG: JPMorgan Chase & Co. raised target to $90 from $85 with a Neutral rating.

PENN Entertainment – PENN: Mizuho raised target to $22 from $19 with an Outperform rating.

PepsiCo – PEP: Piper Sandler raised target to $181 from $172 with an Overweight rating.

Pharming Group – PHAR: HC Wainwright set a $37 target with a Buy rating.

PulteGroup – PHM: UBS Group reiterated a Buy rating.

Piper Sandler Companies – PIPR: Goldman Sachs Group lowered target to $392 from $461 with a Buy rating.

PJT Partners – PJT: UBS Group lowered target to $151 from $180 with a Neutral rating.

Planet Fitness – PLNT: KeyCorp initiated coverage with Overweight rating and $100 target.

Pliant Therapeutics – PLRX: Piper Sandler lowered target to $3 from $4 with an Overweight rating.

Permian Resources – PR: Piper Sandler raised target to $27 from $24 with an Overweight rating.

Prime Medicine – PRME: Oppenheimer initiated coverage with an Outperform rating and $11 target.

ProQR Therapeutics – PRQR: Oppenheimer initiated coverage with an Outperform rating and $9 target.

Phillips 66 – PSX: Goldman Sachs Group raised target to $186 from $168 with a Neutral rating.

Perella Weinberg Partners – PWP: Goldman Sachs Group lowered target to $18.50 from $21.50 with a Sell rating.

Ultragenyx Pharmaceutical – RARE: JPMorgan Chase & Co. lowered target to $74 from $120 with an Overweight rating.

Radian Group – RDN: UBS Group lowered target to $39 from $41 with a Neutral rating.

Regions Financial – RF: Brean Capital initiated coverage with a Neutral rating

Rivian Automotive – RIVN: Benchmark reiterated a Buy rating; Leerink Partners reiterated an Outperform rating.

Range Resources – RRC: Piper Sandler raised target to $42 from $41 with a Neutral rating.

Rentokil Initial – RTO: UBS Group upgraded rating from Neutral to Buy.

Ryanair – RYAAY: Evercore upgraded rating from In-Line to Outperform with $80 target.

Rhythm Pharmaceuticals – RYTM: Wells Fargo & Company raised target to $143 from $136 with Overweight; Telsey Advisory Group set $143 target.

Smith Douglas Homes – SDHC: Wells Fargo & Company lowered target to $14 from $18 with Equal Weight rating.

Vivid Seats – SEAT: Bank of America reiterated an Underperform rating with $5.65 target.

Stitch Fix – SFIX: Telsey Advisory Group lowered target to $5 from $6 with a Market Perform rating.

Shell – SHEL: Piper Sandler raised target to $106 from $89 with Overweight rating.

Shopify – SHOP: Piper Sandler initiated coverage with Overweight rating and $165 target.

SLB – SLB: Sanford C. Bernstein raised target to $56.10 from $52.30 with an Outperform rating.

Solid Biosciences – SLDB: Chardan Capital reiterated a Buy rating with a $15 target.

Sarepta Therapeutics – SRPT: Mizuho set a $31 target.

Silver Standard Resources – SSRM: CIBC upgraded rating from Neutral to Sector Outperform with $48 target.

SURO Capital – SSSS: Citizens Jmp raised target to $13 from $11 with a Market Outperform rating.

Suncor Energy – SU: Goldman Sachs Group raised target to $62 from $55 with a Buy rating.

TAT Technologies – TATT: Benchmark raised target to $66 from $58 with a Buy rating.

Bancorp – TBBK: Piper Sandler initiated coverage with Overweight rating and $66 target.

Atlassian – TEAM: Mizuho lowered target to $185 from $205 with Outperform; Wolfe Research reiterated Outperform with $100 target.

Tenet Healthcare – THC: Mizuho raised target to $265 from $235 with Outperform; Guggenheim raised target to $283 from $271 with Buy.

Tenaya Therapeutics – TNYA: Chardan Capital reiterated Buy with $8 target; William Blair reiterated Outperform; Leerink Partners reiterated Outperform with $2 target.

Tapestry – TPR: Argus set a $165 target.

Trustmark – TRMK: Brean Capital initiated coverage with Buy rating.

TPG RE Finance Trust – TRTX: Citizens Jmp upgraded rating from Market Perform to Outperform with $10 target; Citigroup upgraded from Market Perform to Outperform.

Travelers Companies – TRV: Brean Capital initiated coverage with Neutral rating.

ServiceTitan – TTAN: BTIG Research lowered target to $105 from $130 with Buy rating.

TechTarget – TTGT: Needham & Company reiterated Buy rating; Lake Street Capital lowered target to $8 from $10 with Buy.

United Airlines – UAL: Jefferies Financial Group lowered target to $125 from $148 with Buy rating.

UniFirst – UNF: Barclays raised target to $280 from $250 with Equal Weight rating.

United Natural Foods – UNFI: Deutsche Bank raised target to $46 from $40 with Hold rating.

United Therapeutics – UTHR: Cantor Fitzgerald raised target to $625 from $525 with Overweight rating.

Telefonica Brasil – VIV: Barclays reiterated Equal Weight rating with $16 target.

Valero Energy – VLO: Goldman Sachs Group raised target to $237 from $203 with Buy rating.

Viper Energy – VNOM: Piper Sandler raised target to $68 from $64 with Overweight rating.

VSE – VSEC: William Blair reiterated an Outperform rating.

Verastem – VSTM: BTIG Research initiated coverage with Buy rating and $19 target.

vTv Therapeutics – VTVT: Evercore initiated coverage with Outperform rating and $44 target.

Verizon Communications – VZ: Raymond James Financial reiterated Outperform rating with $56 target.

Waystar – WAY: Deutsche Bank lowered target to $37 from $42 with Buy rating.

Workday – WDAY: Loop Capital set a $210 target.

Western Midstream Partners – WES: JPMorgan Chase & Co. lowered target to $43 from $44 with Neutral rating.

Wix.com – WIX: Piper Sandler initiated coverage with Neutral rating.

Westlake – WLK: Citigroup raised target to $130 from $124 with Buy rating.

Wealthfront – WLTH: Keefe, Bruyette & Woods reiterated Market Perform; Wells Fargo lowered target to $12 from $12.50 with Overweight; JPMorgan lowered target to $10 from $16 with Overweight; Goldman Sachs lowered target to $10.50 from $12 with Neutral rating.

Petco Health and Wellness – WOOF: Jefferies Financial Group upgraded rating from Hold to Buy with $5 target.

WesBanco – WSBC: Raymond James Financial reiterated Strong-Buy rating with $41 target.

Williams-Sonoma – WSM: Telsey Advisory Group reiterated Outperform rating with $220 target

Woodward – WWD: UBS Group reiterated Buy rating.

Xcel Energy – XEL: Argus set an $86 target.

Exxon Mobil – XOM: Piper Sandler raised target to $186 from $145 with Overweight rating.

Xponential Fitness – XPOF: KeyCorp initiated coverage with Sector Weight rating.

Full Truck Alliance – YMM: Morgan Stanley reiterated Overweight rating.

JOYY – YY: Benchmark reiterated Buy rating.

Zions Bancorporation, N.A. – ZION: Brean Capital initiated coverage with Neutral rating.

The post Latest US Analyst Ratings: March 12th, 2026 appeared first on Stock Target Advisor.